CARNITOR TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
23-04-2019
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
LEVOCARNITINE
Inapatikana kutoka:
LEADIANT BIOSCIENCES, INC
ATC kanuni:
A16AA01
INN (Jina la Kimataifa):
LEVOCARNITINE
Kipimo:
330MG
Dawa fomu:
TABLET
Tungo:
LEVOCARNITINE 330MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
90 TABLETS
Dawa ya aina:
Prescription
Eneo la matibabu:
CALORIC AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0127168002; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2017-11-02
Tabia za bidhaa
CARNITOR
®
Product Monograph
Page 1 of 26
PRODUCT MONOGRAPH
Pr
CARNITOR
®
Levocarnitine Tablets USP 330 mg
Levocarnitine Oral Solution USP 1 g / 10 mL (100 mg / mL)
Levocarnitine Injection USP 1 g / 5 mL (200 mg / mL)
Amino Acids and Derivatives
Leadiant Biosciences, Inc.
2000 Ellesmere Road, Unit 16
Scarborough, Ontario
M1H 2W4
Date of Revision: April 23, 2019
Submission Control No: 222342
CARNITOR
®
Product Monograph
Page 2 of 26
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................................
4
ADVERSE REACTIONS
.................................................................................................................
6
DRUG INTERACTIONS
...............................................................................................................
12
DOSAGE AND ADMINISTRATION
...........................................................................................
12
OVERDOSAGE
.............................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
15
STORAGE AND STABILITY
.......................................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................... 17
PART II: SCIENTIFIC INFORMATION
.................................................................................
Soma hati kamili
